Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.32M | $ 2.24M | $ 23.90M | $ 60.88M | $ 55.24M |
| Gross Profit | $ -3.47M | $ -1.51M | $ 20.61M | $ 59.22M | $ 55.24M |
| Operating Income | $ -42.91M | $ -38.08M | $ -28.92M | $ -13.39M | $ 20.56M |
| EBITDA | $ -28.99M | $ -38.13M | $ -15.12M | $ -15.20M | $ 21.14M |
| Net Income | $ -34.11M | $ -42.19M | $ -18.74M | $ -17.44M | $ 20.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 20.76M | $ 56.57M | $ 15.05M | $ 33.21M | $ 12.61M |
| Total Assets | $ 44.20M | $ 83.94M | $ 50.90M | $ 79.37M | $ 56.54M |
| Total Debt | $ 4.67M | $ 5.91M | $ 5.93M | $ 6.74M | $ 8.13M |
| Net Debt | $ -4.23M | $ -50.66M | $ -9.12M | $ -26.46M | $ -4.48M |
| Total Liabilities | $ 18.23M | $ 26.64M | $ 19.85M | $ 40.82M | $ 17.53M |
| Stockholders' Equity | $ 25.97M | $ 57.30M | $ 31.06M | $ 38.55M | $ 39.01M |
| Cash Flow | |||||
| Free Cash Flow | $ -34.63M | $ -25.32M | $ -7.19M | $ -7.19M | $ -2.73M |
| Operating Cash Flow | $ -34.29M | $ -25.12M | $ 3.76M | $ 3.76M | $ 10.00M |
| Investing Cash Flow | $ -11.96M | $ -152.70K | $ -10.94M | $ -10.94M | $ -12.72M |
| Financing Cash Flow | $ -1.17M | $ 66.77M | $ 34.12M | $ 34.12M | $ 8.98M |
SAB Biotherapeutics Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.